overall survival
Onco
Daily
Twitter
Facebook
Youtube
RSS Feed
Linkedin
Facebook
RSS
Twitter
Youtube
Linkedin
July, 2024
July 2024
M
T
W
T
F
S
S
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
« Jun
overall survival
May 20, 2024, 14:02 |
Blog
Talha Badar: Rx of Lower risk MDS, non del 5q, failing ESA/luspatercept
Talha Badar, Assistant Professor at Mayo Clinic Comprehensive Cancer Center shared a thread on X:…
May 18, 2024, 01:12 |
Opinion
Results from the IMpassion132 trial presented at ESMO Breast 24
The European Society for Medical Oncology (ESMO) shared on LinkedIn: “Results from the IMpassion132 trial presented…
May 12, 2024, 13:31 |
Blog
Stephen Liu: Update from phase 3 IMscin001 trial JTO and JTO CRR
Stephen Liu, Director of Thoracic Oncology and Developmental Therapeutics at Georgetown University, shared on X/Twitter: “Update from…
Apr 28, 2024, 10:18 |
Blog
Stephen Liu: Interesting look at immediate versus deferred systemic therapy in patients with pleural mesothelioma at Clinical Lung Cancer
Stephen Liu, Director of Thoracic Oncology and Developmental Therapeutics at Georgetown University, shared on X/Twitter: "Certainly confounders…
Apr 7, 2024, 11:53 |
Insight
Roberto Leon-Ferre: The role of immune activation on the prognosis of early TNBC if chemo is not given?
Roberto Leon-Ferre, Assistant Professor at Mayo Clinic, shared on X/Twitter: "What is the role of…
Feb 25, 2024, 14:57 |
Blog
Robert Francomano: Significant change in regulatory priorities by the FDA
Robert Francomano, Chief Commercial Officer at SELLAS, shared on LinkedIn: "The recent emphasis by the…
Dec 10, 2023, 16:59 |
Insight
Yüksel Ürün: MFS continues to be a reliable predictor for overall survival
Yüksel Ürün, Medical Oncologist at Ankara University, shared on X: “With better access to docetaxel…
1
2
3
All:
27
Posts:
21 - 30
Eliot Levitt: The Yvonne Awards demonstrate something that it doesn't hurt to be reminded of
New data from the NEST clinical trial was presented at ESMOGI24 - Agenus
Zainab Shinkafi-Bagudu's latest commentary on Cervical Cancer Elimination Forum
New Paper Alert! Amivantamab-Lazertinib Improves Outcomes in High-Risk EGFR-Mutant NSCLC Subgroups: MARIPOSA Study Results
Learn more about overcoming barriers to immunotherapy for microsatellite stable colorectal cancer
Facebook
RSS Feed
Twitter
Linkedin
Youtube